News – Page 898 – Endpoints News

Bristol-Myers Squibb boasts impressive 5-year melanoma OS data on Opdivo/Yervoy combo, though it still can't pinpoint ...

6 years ago

Amgen isn’t wowing ESMO with the latest KRAS G12C update — but maybe there are more important issues at stake

6 years ago

Bristol-Myers Squibb's Opdivo couldn't topple Nexavar in HCC — but will better safety profile win over physicians?

6 years ago

NASH hopeful Genfit promotes Dean Hum to president; Immune Therapeutics CEO passes baton to successor

6 years ago

OND reorganization moves forward

6 years ago

Pfizer's JAK inhibitor clears second pivotal eczema study, but can it topple Regeneron's Dupixent?

6 years ago

A year into Albert Bourla’s reign, Ian Read leaves all of Pfizer in the new CEO’s control

6 years ago

Led by BioNTech, six biotechs line up for October IPOs

6 years ago

Darzalex from J&J, Genmab scores FDA approval in frontline multiple myeloma use as Sanofi rival looms

6 years ago

Deerfield bets on New York City, blueprints $635M biotech hub in midtown Manhattan

6 years ago

Biotechs are spending record sums on R&D — should that worry you at least a little?

6 years ago

Jazz gets its narcolepsy upgrade drug decked out for the FDA as clock ticks down on cash cow patents

6 years ago

Deep impact: Drugs to watch in Q3 — PBM analysis

6 years ago

T3 Pharmaceuticals completes second financing round; Moderna, Harvard Medical School to tackle immunological diseases

6 years ago

Oncologists listen when the FDA speaks, even after a drug hits the market

6 years ago

Meissa obtains $30M Series A from Morningside to test synthetic biology approach to 'elusive' RSV vaccines

6 years ago

A microcap biotech salves old wounds with positive PhII report on status epilepticus, but plenty of questions remain

6 years ago

Takeda turns to emerging markets, Western Europe in scramble to offload Shire debt — report

6 years ago

GSK infuses $120M into next-gen manufacturing facilities at Upper Merion, PA

6 years ago

Republicans rebuke Pelosi drug pricing bill

6 years ago

Enanta's NASH drug barely meets main goal in mid-stage study

6 years ago

Is the FTC about to force Roche to divest a key hemophilia program before green-lighting Spark buyout?

6 years ago

BioNTech lays out plans for $251M IPO; Trio teams up to form joint lab to research chronic lung diseases

6 years ago

After rocky hep C path, Achillion finds surer footing with FDA breakthrough status

6 years ago

First page Previous page 895 896 897898899 900 901 Next page Last page